Zydus Lifesciences, an innovation-led life-sciences company with an international presence, has signed an agreement with ...

As part of this agreement, Zydus will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics' broadly validated diagnostic platforms, MyRisk Hereditary Cancer ...

Trailblazing geneticist Pengfei Liu, Ph.D., Associate Professor in the Department of Molecular and Human Genetics at Baylor ...

Australian scientists have identified the key genetic drivers behind long COVID, revealing why some people continue to ...

SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight ...

Emerging markets, breakthrough technologies, and strategic M&A reshape competitive landscapeThe global molecular cytogenetics ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) has issued an announcement. Zydus Lifesciences has signed an exclusive agreement with US-based ...

We searched for evidence from studies known as 'clinical trials' that compared rapid TB tests with traditional methods of testing for TB, like smear microscopy and culture. We summarised the findings ...

Zydus Lifesciences has partnered with US-based Myriad Genetics to bring advanced cancer risk and prognostic tests to India, aiming to boost personalized oncology care.

Investigations suggest V2P may be efficiently applied for the automated identification of causal variants in simulated and actual patient sequencing data across phenotypes.